Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial ResultsGlobeNewsWire • 02/24/22
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential24/7 Wall Street • 02/19/22
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical DevelopmentGlobeNewsWire • 02/01/22
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid LeukemiaGlobeNewsWire • 12/06/21
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742GlobeNewsWire • 11/29/21
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial ResultsGlobeNewsWire • 11/09/21
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus' PlatformGlobeNewsWire • 11/08/21
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in OncologyGlobeNewsWire • 11/04/21
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021GlobeNewsWire • 09/30/21
Kronos Bio Reports Recent Business Progress and Second Quarter Financial ResultsGlobeNewsWire • 08/12/21
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)GlobeNewsWire • 07/27/21
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day TodayGlobeNewsWire • 05/25/21
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D DayGlobeNewsWire • 05/11/21
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021GlobeNewsWire • 04/10/21
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/23/21
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified CancersGlobeNewsWire • 03/10/21
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)GlobeNewsWire • 03/04/21
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified CancersGlobeNewsWire • 02/25/21
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care ConferenceGlobeNewsWire • 02/22/21
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified CancersGlobeNewsWire • 12/07/20